bioRxivCancer BiologyPreprint
A "cooperative collaboration" between HAND2 and MYCN shapes neuroblastoma cell identity
M. Xu, M. Sun, X. Zhang, R. Nguyen, H. Lei, J. F. Shern, C. J. Thiele, Z. Liu
Abstract
Noradrenergic neuroblastoma (NB) is characterized by a core transcriptional regulatory circuitry (CRC) comprised of transcription factors (TFs) such as PHOX2B, HAND2 and GATA3, which form a network with MYCN. Physiological levels of MYCN mainly binds to promoters but aberrantly upregulated MYCN in NB also binds to enhancers. How MYCN invades enhancers, and what role the CRC TFs play in this process is unknown. Here we find that HAND2 assists MYCN to invade enhancers through an "indirect cooperative" TF-DNA binding mechanism. HAND2 cooperates with MYCN to compete with nucleosomes and regulate global gene transcription. The treatment of NB with an Aurora A kinase inhibitor plus HDAC inhibitor potently downregulates both MYCN and the CRC TFs and suppresses MYCN-amplified NB tumor growth. Our study identifies a "cooperative collaboration" among MYCN and CRC TFs and the simultaneous targeting these TFs is an effective way to treat this aggressive pediatric tumor.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes
Z. Liu, X. Zhang, … C. J. Thiele·bioRxiv·Jul 11, 2023
- Inhibition of OCT4 Binding at the MYCN Locus Induces Neuroblastoma Cell Death Accompanied by Downregulation of Transcripts with High-Open Reading Frame Dominance
K. Nakatani, H. Kogashi, … Y. Suenaga·bioRxiv·Jun 8, 2023
- Phosphorylation of MYCN and MAX by PAK family kinases is a novel tumor-suppressor mechanism in neuroblastoma with potential therapeutic implications.
E. J. Rozen, K. Wigglesworth, J. M. Shohet·bioRxiv·Dec 4, 2023
- BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states
Irene Felipe‐Abrio, Jaime Martínez-de-Villarreal, … Francisco X. Real·bioRxiv·Feb 11, 2024
- Dual BRD4 and AURKA Inhibition is Synergistic against MYCN-amplified and nonamplified Neuroblastoma
J. Felgenhauer, L. Tomino, … N. Shah·bioRxiv·Mar 5, 2018
- MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma
M. Zeineldin, S. Federico, … M. Dyer·bioRxiv·Jul 29, 2018